Rasmussen Thomas, Hansson Lotta, Osterborg Anders, Johnsen Hans Erik, Mellstedt Håkan
Herlev Hospital, University of Copenhagen, Denmark.
Blood. 2003 Jun 1;101(11):4607-10. doi: 10.1182/blood-2002-06-1925. Epub 2003 Feb 6.
Myeloma cells express the idiotype (Id)-specific antigen that may be targeted by Id vaccination. Six patients with stage I IgG myeloma were immunized with the autologous purified M component together with the adjuvant cytokines interleukin 12 (IL-12) alone or in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF). The effect of Id vaccination on circulating clonal tumor B cells was monitored by a real-time allele-specific oligonucleotide polymerase chain reaction method. No other treatment was given. Reduction of blood tumor mass was observed in 4 of 6 patients, with one patient achieving a complete molecular remission in blood. In 3 of these 4 patients an Id-specific T-cell response was induced. In the remaining 2 patients with an unchanged level of blood tumor cells, one patient mounted a T-cell response, whereas the other did not. No significant change in the serum M protein level was noted. Id vaccination may target clonal B cells, suggesting that this strategy might be conducive to achieving tumor control. The clinical significance of these findings remains to be established.
骨髓瘤细胞表达独特型(Id)特异性抗原,可通过Id疫苗接种进行靶向治疗。6例I期IgG骨髓瘤患者接受了自体纯化的M成分免疫治疗,同时单独使用佐剂细胞因子白细胞介素12(IL-12)或与粒细胞巨噬细胞集落刺激因子(GM-CSF)联合使用。通过实时等位基因特异性寡核苷酸聚合酶链反应方法监测Id疫苗接种对循环克隆性肿瘤B细胞的影响。未给予其他治疗。6例患者中有4例观察到血液肿瘤肿块减少,其中1例患者血液中实现了完全分子缓解。在这4例患者中的3例诱导了Id特异性T细胞反应。在其余2例血液肿瘤细胞水平未改变的患者中,1例患者产生了T细胞反应,而另1例未产生。血清M蛋白水平未观察到显著变化。Id疫苗接种可能靶向克隆性B细胞,表明该策略可能有助于实现肿瘤控制。这些发现的临床意义仍有待确定。